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May-Hui Ding, BS, Eloy G. Lozoya, Rene N. Rico, and Sue Anne Chew, PhD

Angiogenesis is an important process in tissue repair and regeneration as blood vessels are integral to supply
nutrients to a functioning tissue. In this review, the application of microRNAs (miRNAs) or anti-miRNAs that
can induce angiogenesis to aid in blood vessel formation for vascular tissue engineering in ischemic diseases
such as peripheral arterial disease and stroke, cardiac diseases, and skin and bone tissue engineering is discussed. Endothelial cells (ECs) form the endothelium of the blood vessel and are recognized as the primary cell
type that drives angiogenesis and studied in the applications that were reviewed. Besides ECs, mesenchymal
stem cells can also play a pivotal role in these applications, specifically, by secreting growth factors or cytokines
for paracrine signaling and/or as constituent cells in the new blood vessel formed. In addition to delivering
miRNAs or cells transfected/transduced with miRNAs for angiogenesis and vascular tissue engineering, the
utilization of extracellular vesicles (EVs), such as exosomes, microvesicles, and EVs collectively, has been
more recently explored. Proangiogenic miRNAs and anti-miRNAs contribute to angiogenesis by targeting the
3¢-untranslated region of targets to upregulate proangiogenic factors such as vascular endothelial growth factor
(VEGF), basic fibroblast growth factor, and hypoxia-inducible factor-1 and increase the transduction of VEGF
signaling through the PI3K/AKT and Ras/Raf/MEK/ERK signaling pathways such as phosphatase and tensin
homolog or regulating the signaling of other pathways important for angiogenesis such as the Notch signaling
pathway and the pathway to produce nitric oxide. In conclusion, angiogenesis-inducing miRNAs and antimiRNAs are promising tools for vascular tissue engineering for several applications; however, future work
should emphasize optimizing the delivery and usage of these therapies as miRNAs can also be associated with
the negative implications of cancer.
Keywords: microRNA, angiogenesis, vascular tissue engineering, blood vessel, endothelial cells, mesenchymal
stem cells
Impact Statement

Recent review articles have discussed the utilization of proangiogenic microRNAs (miRNAs) in angiogenesis and osteogenesis coupling and for bone tissue engineering applications. In this review, we discuss proangiogenic miRNAs that have
been applied in vascular tissue engineering for different applications (i.e., not only for bone tissue engineering but also for
peripheral arterial disease and stroke, cardiac diseases, and skin tissue engineering). This work provides an overview of the
current state of utilization of proangiogenic miRNAs and emphasizes the importance of accuracy and dose of administration
in designing future applications as these miRNAs can also be associated with the negative implications of cancer.
Angiogenesis

N

eovascularization or new blood vessel formation is
critical for the survival of cells and for tissue to function adequately as oxygen and nutrient diffusion are limited
to *150–200 mm.1 Blood vessels are formed through the
migration and proliferation of endothelial cells (ECs) and

the formation of tubular structures, which are modulated by
different growth factors, cytokines, adhesion molecules,
integrins, and enzymes.2 Neovascularization can occur by
(1) angiogenesis, which is the formation of new blood vessel
from preexisting blood vessels, and (2) vasculogenesis,
which is the formation of new blood vessel de novo by selfassembly of endothelial or endothelial progenitor cells.3,4
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There are two types of angiogenesis: (1) sprouting angiogenesis, a better understood process where sprouts of ECs add
blood vessels to tissue areas devoid of blood vessels, and (2)
intussusceptive angiogenesis, a more recently discovered process in which blood vessels form through a splitting process.5
Both angiogenesis and vasculogenesis occur in embryonic development; however, in adults, transient formation of blood
vessel occurs only in certain situations such as in the placenta
during pregnancy and mainly by angiogenesis.6 Angiogenesis is
vital in adults during wound healing and postinjury regeneration, and also occurs during tumor growth. In contrast to tumor
angiogenesis, which produces a large number of immature and
disorganized vessels, reparative angiogenesis produces the
functional and interconnected vessels fundamental in tissue
regeneration.7,8
Angiogenesis in tissue regeneration has positive implications in myocardial ischemia and the engineering of threedimensional (3D) tissue engineering applications such as for
bone tissue. The lack of vasculature during the bone regeneration process can decrease bone formation and mass and formation of fibrous tissue.2 Thus, angiogenesis is vital in bone
tissue engineering to ensure that the bone repair with tissueengineered systems is not impaired. Like in bone tissue engineering, it is also important to prevascularize other tissue engineering constructs, such as skin, before implantation to
ensure better success of the application in vivo. Without the
integration of blood vessels, the size and complexity of tissue
engineering constructs and their subsequent success may be
hindered from the lack of nutrient and oxygen supply that
blood vessels deliver. The reduction of the delivery of oxygen
can affect cells and tissue during wound healing and cardiac
diseases such as myocardial infarction (MI), resulting in activation of complex signaling pathways to overcome the hypoxia at the impaired environment, to restore oxygen and
nutrient homeostasis.9 Thus, applications that can help induce
angiogenesis during these processes and diseases are vital.
The Overexpression of microRNAs for Vascular
Tissue Engineering

microRNAs (miRNAs) are short (*22 nucleotides in
length) noncoding single-strand RNAs that act as posttranscriptional gene regulators by binding complementary
sequences typically in the 3¢-untranslated region (UTR) of
target messenger RNAs (mRNAs). miRNAs have been
shown to play essential roles in diverse biological processes,
including osteogenesis and angiogenesis, by regulating different cellular activity such as development, differentiation,
proliferation, metabolism, and apoptosis.10 miRNA binding
to the 3¢-UTR of mRNAs results in either the degradation of
the target mRNA or inhibit translation of the mRNA into the
protein of interest.11,12 By repressing the inhibitors of angiogenesis, miRNAs can upregulate the expression of
angiogenesis-inducing growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth
factor (bFGF), or transcription factors, such as hypoxiainducible factor-1 (HIF-1), which can enhance angiogenesis.
Extensive research has been focused on delivering growth
factors for tissue engineering and regeneration. However,
shortcomings associated with delivering growth factors in
the protein form, such as the short half-life of protein and
cost and difficulty of manufacturing these recombinant
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proteins, have led to the search of other methods of delivering bioactive factors for tissue engineering. By controlling
the production of the bioactive factors in vivo via gene delivery (i.e. plasmid DNA, siRNA or miRNA) the proteins
can be delivered in a more biologically active form13 with
more precise post-translational modification and tertiary
structure formation14,15 compared to the exogenous growth
factors that may be altered through the delivery process.
Compared to plasmid DNA or siRNA, which regulates one
specific mRNA, miRNAs can regulate multiple mRNAs or
genes. The regulation of angiogenesis involves many different
genes, and thus, the focus on a single target is generally insufficient or inefficient.16 Instead of utilizing plasmid DNA or
siRNA to regulate one specific mRNA, miRNA-based therapies can be used to influence a regulatory sequence resulting in
regulation of a whole pathway or multiple pathways. Therefore, the overexpression of miRNAs to regulate in vivo production of their target genes vital in vascular tissue engineering
may be a promising alternative to current traditional treatments
of delivering growth factors as recombinant protein or delivering the plasmid encoding these proteins. Table 1 provides a
summary of the difference between these different bioactive
factors (i.e., protein, plasmid DNA, siRNA, and miRNA).
In this review, we discuss miRNAs that can induce angiogenesis, which have been utilized in applications where vascular
tissue engineering is needed (i.e., ischemic diseases, cardiac
diseases, and skin and bone tissue engineering). We discuss the
different miRNAs or anti-miRNAs, nonviral or viral gene delivery vectors, biomaterial scaffolds or injection methods, targeting agents, and cell types used in these applications. We also
discuss the role of mesenchymal stem cells (MSCs) in these
applications, particularly their role in paracrine signaling of
secreted growth factors or cytokines and contribution as constituent cells in the new blood vessels that are formed. We also
discuss the utilization of extracellular vesicles (EVs), such as
exosomes, microvesicles, or EVs collectively, for angiogenesis
and vascular tissue engineering. Figure 1 depicts the different
applications of these angiogenesis-inducing miRNAs and antimiRNAs in vascular tissue engineering.
Frohlich published an article on miRNAs that have been
identified to be involved in the coupling of osteogenesis and
angiogenesis,17 and Hosseinpour et al. evaluated miRNAs
used in the regulation of angiogenesis in bone regeneration in
2019.18 Urbich et al. reviewed miRNA in vascular diseases,
inflammation, and angiogenesis, which was published much
earlier (i.e., 2008).19 In this work, we focused on discussing
publications that not only have identified the proangiogenic
miRNAs but also have applied them to a model or a disease
that requires aid in vascular tissue engineering, and not just
limited to bone tissue engineering applications. Furthermore,
we also discussed the role MSCs play in angiogenesis, as there
is conflicting evidence on their contribution in blood vessel
formation, and also discuss the more recent application of EVs
in angiogenesis for vascular tissue enginering.
Targets and Mechanisms

Table 2 summarizes the direct targets and mechanisms for
the proangiogenic miRNAs and anti-miRNAs that were reviewed in this article. The VEGF pathway is the primary
hormonal pathway controlling angiogenesis. Among the
different isoforms of VEGF, VEGF-A is the central isoform
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Table 1. Differences Between the Application of Traditional Approaches Versus microRNAs
for Tissue Engineering
Protein
Target

Delivers one
specific protein
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Stability/half-life Short half-life
Manufacturing
High cost and is
more difficult to
manufacture
Protein delivery Exogeneous protein
or production
delivery

Size

Can be large

Plasmid DNA

siRNA

Regulates the
expression of one
specific mRNA
Longer half-life
Lower cost and less
difficult to
manufacture
Protein produced
in vivo, proteins can
be delivered in a
more biologically
active form with
more precise posttranslational
modification and
tertiary structure
formation.

Usually large

that regulates angiogenesis and EC growth.20 VEGF has
also been associated with increased cell viability, proliferation, and decrease apoptosis in MSCs.21,22 VEGF functions
by binding to VEGF receptors (VEGFR), which in turn
activates multiple downstream pathways, including Ras/Raf/
MEK/ERK, PI3K/Akt, or Src/FAK signaling pathways,
which lead to angiogenesis23 through the regulation of the
fate of ECs.24 There are several miRNAs (i.e., miRNA-34,
miRNA-195, and miRNA-377) that directly target the 3¢UTR of VEGF and suppress its expression (Table 2). To
enhance angiogenesis, the inhibitors of these miRNAs can
be used for therapeutic applications. miRNA-378 targets the
3¢-UTR of VEGF, competing with miRNA-125a, an inhibitor of VEGF expression. By competing for the same seed
site, miRNA-378 can strengthen the expression of VEGF.25

Regulates the expression
of one specific mRNA

microRNA
Regulates the expression
of multiple mRNAs

Longer half-life
Longer half-life
Lower cost and less
Lower cost and less
difficult to manufacture
difficult to manufacture
Protein production is
Protein production is
prevented
prevented
This could lead to
This could lead to
upregulation of the
upregulation of the
production of other
production of other
proteins which will be
proteins which will be
produced in vivo,
produced in vivo,
proteins can be
proteins can be
delivered in a more
delivered in a more
biologically active form
biologically active form
with more precise postwith more precise posttranslational
translational
modification and tertiary
modification and tertiary
structure formation.
structure formation.
Small
Small

It has been depicted that the levels of circulating growth
factors such as VEGF are not downregulated in MI and
peripheral arterial disease (PAD), so impairment of angiogenesis could be due to downstream signaling instead of
decrease in the expression of these growth factors.24 The 3¢UTR of phosphatase and tensin homolog (PTEN) is the
target for several miRNAs (i.e., miRNA-21, miRNA-26a,
and miRNA-130a) (Table 2). Overexpression of PTEN inhibits the PI3K/AKT pathway, which is important in enhancing angiogenesis through regulating EC survival,
migration, and capillary-like structure (CLS) formation.26
By suppressing the expression of PTEN with a miRNA, the
signaling of the PI3K/Akt pathway can be activated. Although PTEN is a well-known negative regulator of the
PI3K/AKT pathway, it has also more recently been

FIG. 1. Schematic summarizing the applications of
proangiogenic microRNAs
or anti-microRNAs for vascular tissue engineering.

Table 2. The Target and Mechanism of the Proangiogenic microRNAs and Anti-microRNAs Used
for Vascular Tissue Engineering
miRNA
miRNA-21

miRNA-26a
miRNA-31
Anti-miRNA-34
Anti-miRNA-92a
miRNA-93
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miRNA-125a
miRNA-126

miRNA-130a
miRNA-132
Anti-miRNA135a-3p
Anti-miRNA-143
miRNA-145
miRNA-146a
miRNA-181b-5p
Anti-miRNA-195
miRNA-199-3p
Anti-miRNA-200b
Anti-miRNA-210
Anti-miRNA-222
Anti-miRNA-377
miRNA-378
Anti-miRNA-493

Mechanism
miRNA-21 targets the 3¢-UTR of PTEN and suppresses its expression.27 PTEN downregulates PI3K/AKT
and Ras/Raf/MEK/ERK signaling pathways, and also leads to the inhibition of HIF-1a and VEGF
expression.34,136
miRNA-21 also targets 3¢-UTR of SPRY1 and suppresses its expression.137 SPRY1 inhibits the
proangiogenic factors, VEGF, FGF, and EGFL7, through the Raf/MEK/ERK signaling pathway.137,138
miRNA-26a targets the 3¢-UTR of PTEN and suppresses its expression.139 PTEN downregulates PI3K/AKT
and Ras/Raf/MEK/ERK signaling pathways, and also leads to the inhibition of HIF-1a and VEGF
expression.34,136
miRNA-31 targets the 3¢-UTR of FIH1 and suppresses its expression.32 FIH1 inhibits the transcriptional
activity of HIF-1, a proangiogenic factor involved in angiogenesis.33,34
miRNA-34 targets the 3¢-UTR of VEGFs, vinculin, protein O-fucosyltransferase, Notch1, and semaphorin
4B, which are important for angiogenesis and cardiac function.57
miRNA-92a targets the 3¢-UTR of ITGA5.40,41 Suppression of ITGA5 leads to the downregulation of eNOS,
which is important for vascular tone and postnatal neovascularization.42,43
miRNA-93 targets the 3¢-UTR of CDKN1A and suppresses its expression.53 CDKN1A (p21) counteracts
actions of VEGF and MAPK.140
miRNA-125a targets the 3¢-UTR of DLL4 and suppresses its expression.37 DLL4 is an angiogenic inhibitor
and a ligand of the Notch signaling pathway that inhibits endothelial tip cell formation in
angiogenesis.37,38
miRNA-126 targets the 3¢-UTR of Spred-1141,142 and PI3KR2 (p85-beta)141 and suppresses their expression.
Spred-1 and PI3KR2 suppress VEGF and FGF142 and VEGF-dependent PI3K/AKT and Ras/Raf/MEK/
ERK signaling.141
miRNA-126 also targets the 3¢-UTR of PTPN9 and suppresses its expression.51 PTPN9 dephosphorylates
VEGFR2, thus inactivating it.143
miRNA-130a targets PTEN and suppresses its expression.26 PTEN downregulates PI3K/AKT and Ras/Raf/
MEK/ERK signaling pathways, and also leads to the inhibition of HIF-1a and VEGF expression.34,136
miRNA-132 targets 3¢-UTR of RASA1 and suppresses its expression.124 RASA1 is a negative regulator of
vascular sprouting and vessel branching through the inactivation of the Ras/Raf/MEK/ERK pathway.
miRNA-135-3p targets the 3¢-UTR of HIP1 and regulates the VEGF-HIP1-p38k signaling axis for
angiogenesis.24
miRNA-143 targets the 3¢-UTR of IGF-IR, a receptor that inhibits the production of nitric oxide and
angiogenesis.44 NO is a multifunctional factor that maintains vascular homeostasis, protects injured
vessels, and regulates cell growth.39
miRNA-145 primary target gene is KLF4, which is associated with SMC contractile phenotype73
miRNA-146a targets the 3¢-UTR of NF2 and suppresses its expression. NF2 is an inhibitor of PAK1,81
which is a component of the Rac-PAK signaling pathway that is important for lumen formation and
angiogenesis in EC function.144
miRNA-181b targets the 3¢-UTR of TRMP7.122 The suppression of TRMP7 promotes the early stages of
angiogenesis, cell proliferation, migration, adhesion, and tube formation, through the Ras/Raf/MEK/ERK
pathway.145,146
miRNA 195 targets the 3¢-UTR of VEGF and suppresses its expression.71 VEGF is a key angiogenic
mediator.71
miRNA-199-3p targets the 3¢-UTR of Sema3A and suppresses its expression.123,147 Sema3A suppresses the
formation of tip cell filopodia,123,147 which are important for vessel sprouting formation, and migration of
ECs.148
miRNA-200b targets v-Ets erythroblastosis virus E26 oncogene homolog 1 (ETS1) and suppresses its
expression.132 ETS1 is a master regulator of EC gene transcription149 that is downstream of VEGF in the
PI3K/AKT and p38 MAPK signaling pathways.150
miRNA-210 targets the 3¢-UTR of Ephrin-A3 (EFNA3) and suppresses its expression.151 EFNA3 is a
glycosylphosphatidylinositol-anchored membrane protein that is vital for stimulation of tubulogenesis
and formation of capillary-like structures, crucial functions in angiogenesis.
miRNA-222 targets the c-kit receptor152 and STAT5A.153 The c-Kit receptor is expressed on ECs and is the
receptor for the angiogenic activity of SCF.152 STAT5A activates bFGF and IL-3, which activates
vascular EC morphogenesis in the STAT5A signaling pathway.153
miRNA-377 targets the 3¢-UTR of VEGF, resulting in suppression of VEGF.58 VEGF is a key angiogenic
mediator.71
miRNA-378 targets the 3¢-UTR of VEGF and competes with miRNA-125a, which inhibits VEGF
expression. By competing for the same seed site, miRNA-378 can strengthen the expression of VEGF.59
miRNA-493 targets the 3¢-UTR of macrophage MIF, an angiogenic regulator, which inhibits angiogenesis
by inhibiting the of PI3K/Akt and Ras/Raf/MEK/ERK pathways.52 It is involved in EC proliferation
migration and tube formation.154

miRNA, microRNA; UTR, untranslated region; PTEN, phosphatase and tensin homolog, HIF-1, hypoxia-inducible factor-1; VEGF, vascular
endothelial growth factor; FGF, fibroblast growth factor; EGFL7, epidermal growth factor-like protein 7; FIH1, factor-inhibiting HIF-1;
ITGA5, integrin subunit alpha5; eNOS, endothelial nitric oxide-synthase; DLL4, delta-like 4; VEGFR, vascular endothelial growth factor
receptor; HIP1, huntingtin-interacting protein 1; IGF-IR, insulin-like growth factor 1 receptor; NO, nitric oxide; KLF4, Krüppler-like factor 4;
SMC, smooth muscle cell; NF2, neurofibromin 2; PAK1, p21-activated kinase-1; EC, endothelial cell; STAT5A, signal transducer and
activator of transcription 5A; SCF, stem cell factor; bFGF, basic fibroblast growth factor; IL, interleukin; MIF, migration inhibitory factor.
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established as a negative regulator of the Ras/Raf/MEK/
ERK pathway. Therefore, the inhibition of PTEN by a
miRNA will also activate the signaling of the Ras/Raf/
MEK/ERK pathway. Besides controlling EC contribution to
angiogenesis, PTEN suppression can also control the fate of
induced pluripotent stem cells (iPSCs). Di Bernardini et al.
demonstrated that miR-21 targets the 3¢-UTR of PTEN,
thereby regulating the PI3K/Akt pathway for iPSC differentiation into ECs.27
In addition to the Ras/Raf/MEK/ERK and PI3K/AKT
pathways, another pathway important for EC migration and
proliferation through VEGF and VEGFR is the VEGFhuntingtin-interacting protein 1 (HIP1)–p38 signaling pathway.24 Icli et al. demonstrated that miRNA-135 regulates the
p38 MAPK signaling pathway in response to VEGF stimulation, but not the ERK1/2 or Akt pathways.24 This is because
miR-135-3p targets the 3¢-UTR of HIP1 and regulates the
VEGF-HIP1–p38 signaling axis.24 Anti-miRNA-135-3p can
prevent the inhibition of HIP1, activating the VEGF-HIP1p38k. Therefore, p38 MAPK signaling resulting from VEGF
stimulation contributes to EC migration and proliferation.24
Hypoxia-inducible factor family of proteins is another
important mediator of angiogenesis, and, in particular,
HIF-1, which is made from the HIF-1a and HIF-1b subunits.9 At normoxia, HIF-1a levels are maintained at a low
level. However, during hypoxic conditions, the degradation
of HIF-1a is inhibited, and heterodimerization with HIF-1b
is constitutively expressed, allowing translocation into the
nucleus. Then, the HIF-1a/b dimer binds to hypoxia response elements, and this results in the transcription of
target genes involved in angiogenesis.28 HIF-1a also plays a
role in activating the transcription of many angiogenesisrelated genes, including VEGF.29,30 HIF-1a can be induced
by hypoxia or loss of PTEN.31 Thus, besides inhibiting the
PI3K/AKT and Ras/Raf/MEK/ERK signaling pathways, the
overexpression of PTEN can also decrease the expression of
both critical angiogenic modulators, HIF-1a and VEGF.
miR-31 targets the 3¢-UTR of factor-inhibiting HIF-1
(FIH1) and suppresses its expression.32 FIH1 inhibits the
transcriptional activity of HIF-1.33,34 Therefore, the overexpression of miR-31 leads to a decrease in FIH1 levels,
which in turn will increase HIF-1 levels.
Besides VEGF, fibroblastic growth factor (FGF) is another growth factor that contributes to angiogenesis.20 The
main signaling pathway for FGF is through its association
with FGFR-1.23 FGF levels can be regulated by proangiogenic miRNAs such as miRNA-21 and miRNA-126, which
target the 3¢-UTR of SPRY-1 and Spred-1, respectively. The
suppressed expression of these targets by the miRNAs increases the expression of FGF. miRNA-222 targets the
3¢-UTR of the signal transducer and activator of transcription 5A (STAT5A), which activates FGF. By inhibiting
miRNA-222, STAT5A suppression by miRNA-222 can be
avoided, which will lead to increased FGF levels.
Another pathway involved in vasculature and angiogenesis is the Notch signaling pathway. Notch signaling decreases the formation of tip cells and reduces the density of
vascular network.35,36 Tip cells are ECs that are located at
the very tip of angiogenic sprouting. Besides binding to the
3¢-UTR seed region of VEGF, miRNA-125a also targets the
3¢-UTR of delta-like 4 (DLL4) and suppresses its expression.37 DLL4 is an angiogenic inhibitor and a ligand of the
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Notch signaling pathway that inhibits endothelial tip cell
formation in angiogenesis.37,38
Nitric oxide (NO) is a multifunctional factor that maintains vascular homeostasis, protects injured vessels, and
regulates cell growth, making it crucial for angiogenesis.39
The production of NO can be regulated by miRNAs as well.
NO is generated by NO synthase (NOS), including endothelial NOS (eNOS). miR-92a targets the 3¢-UTR of integrin
subunit alpha5 (ITGA5).40,41 Suppression of ITGA5 leads to
the downregulation of eNOS, which is important for vascular tone and postnatal neovascularization.42,43 miR-143
targets the 3¢-UTR of insulin-like growth factor (IGF) 1
receptor, a receptor that inhibits the production of NO and
angiogenesis.44
Applications
Vascular disease and tissue engineering

Vascular tissue engineering is needed for many applications, including cardiac diseases, skin tissue engineering in
burn victims or in wound healing, and the regeneration of
3D thick tissues such as bone. The delivery of ECs for
therapeutic vascularization or tissue engineering is often
applied to increase tissue perfusion. However, the utilization
of miRNA to enhance this process can be very promising to
further augment the blood vessel formation and improve the
function of the tissue of interest. Table 3 summarizes the
miRNAs and anti-miRNAs that have been investigated for
different applications to induce angiogenesis for new blood
vessel formation. Devalliere et al. showed that ECs transfected with miRNA-132 to a mouse abdominal wall subcutaneous pocket can improve EC transplantation and
vascularization.45 Small-diameter vascular grafting (diameter 6 mm) can be challenging due to thrombosis and restenosis after graft implantation.46,47 Wen et al. demonstrated
miRNA-145 can be utilized to regulate smooth muscle cell
(SMC) phenotype and proliferation, and thus may be
promising for the regeneration of small-diameter blood
vessels.73
Ischemia results from inadequate blood supply due to the
blockage or damage of blood vessels, which can result in
insufficient supply of oxygen to a certain part of the body
such as the heart, brain, or limbs. Ischemic stroke results
from the blockage of blood vessels in the brain. Even after
timely treatment of the acute phase of ischemic stroke, patients will suffer long-term neurological deficits.48 Thus, in
ischemic stroke patients, blood flow restoration is a key
treatment49 as neovascularization has been shown to result
in positive neurobehavioral outcome after stroke.50 Qu et al.
investigated the utilization of miRNA-126 on ischemic
stroke using a mouse middle cerebral artery occlusion
model.51 They demonstrated that the overexpression of
miRNA-126 resulted in not only increased angiogenesis but
also neurogenesis, which improved neurobehavior. Li et al.
investigated the inhibition of miRNA-493 in a rat middle
cerebral artery occlusion model, which showed increased
capillary density and decreased focal infarct volume, and as
a result, improved neurologic deficit.52
PAD is an atherosclerotic disease that affects the arteries
of the limb53 and induces tissue hypoperfusion, and eventually results in critical limb ischemia.54 Shu et al. demonstrated that overexpression of miRNA-93 can help enhance
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Transfection agent

Cardiac disease

Lipofectamine 2000

Anti-miRNA-493

Intracerebroventricular
injection (local)

VAPG peptide-modified PELCL electrospun
TMC-g-PEG-VAPG
membranes (local)

Collagen fibronectin
gel (local)

Lentiviral vector
brain injection
(local)

miRNA-145

Lentivirus

miRNA-126

Intramuscular
injection (local)

Complexed with
spermidine and then
loaded into PLGA
nanoparticles with
surface-bound cRGD

Lipofectamine
RNAiMax

miRNA-93

Intravenous
injection (systemic)

Matrigel

Biomaterial
vehicle/injection

miRNA-132

GeneTrans II

Anti-miRNA-92a

Vascular tissue engineering
miRNA-21
Lipofectamine
RNAiMAX

miRNA

RBMECs

SMCs

HUVECs

HUVECs

EA.hy926 endothelial
cells

Pluripotent stem cells
(iPSCs)
Paracrine signaling and
differentiation into
vascular lineage
HUVECs

Cell type

Rat middle cerebral
artery occlusion
model
Delivery of miRNA
(in vivo)

In vitro only

Mouse hind limb
ischemic model
Delivery of miRNA
(in vivo)
Mouse middle cerebral
artery occlusion
model
Delivery of miRNA
(in vivo)
Mouse abdominal wall
subcutaneous pocket
model
Delivery of cells
transfected with
miRNA (ex vivo)

Mouse subcutaneous
model
Delivery of cells
transfected with
miRNA (ex vivo)
Mouse hind limb
ischemia model
Delivery of antimiRNA (in vivo)

In vivo model

Increased capillary density
in the IBZ and
decreased focal infarct
volume, improving
neurologic deficit

Increased vessel density/
total lumen area,
increased microvessels
per square millimeter,
and increased smooth
muscle alpha-actin
(SMA) vessels.
Decreased expression of
KLF4, increased
expression of a-SMA
and myocardin,
increased cellular
uptake of SMC, and
modulated SMC
phenotype

Increased vessel length
and diameter, improving
neurobehavioral
recovery

Increased number of
capillaries and smooth
muscle actin-positive
arterioles, reducing toe
necrosis
Enhanced capillary
density, decreasing
muscle necrosis

Induced capillary
formation

Outcome

(continued)

52

73

45

51

53

40

27

References

Table 3. Proangiogenic microRNAs or Anti-microRNAs That Have Been Investigated for Different Vascular Tissue Engineering Applications
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Skin tissue engineering
Anti-miRNA-92a

Dharmafect

Lipofectamine 2000

miRNA-378

Intradermal injection
(systemic)

None

Border area of the
left ventricle
injection (local)

Intramyocardial
injection (local)

siLentFectTM

miRNA-146a

Lentivirus

Re-thoracotomy
and intramyocardial
injection (local)

Lentivirus

miRNA-126

Anti-miRNA-377

Intravenous injection
(systemic)

GeneTrans II

Anti-miRNA-92a

Biomaterial
vehicle/injection
Subcutaneous injection
(systemic)

Transfection agent

Anti-miRNA-34 family None

miRNA

In vivo model

Outcome

None

HEK 293T and H9c2
cells for Luciferasereporter assay

Mouse diabetic db/db
and normal pig
wound models
Delivery of antimiRNA (in vivo)

Increased number and size
of blood vessels in the
mouse diabetic model,
increased granulation
tissue formation,
angiogenesis, and tissue
perfusion, improving
wound healing

Mouse MI and pressure Increased angiogenesis
and increased capillary
overload models
density, improving
Delivery of miRNA
cardiac function
(in vivo)
HUVECs
Mouse acute MI models Enhanced perfused lectinDelivery of miRNA
positive vessels and
(in vivo)
smooth muscle actinpositive arterioles,
improving cardiac
function
Mouse acute MI model Increased number of
Mouse BMMSCs
mature microvessels and
Paracrine signaling, not Delivery of cells
microvessel density,
transfected with
clear if they
improving myocardial
miRNA (ex vivo)
participated in
function
differentiation into
vascular lineage
Increased formation of
Human BMMSCs
Rat I/R injury animal
vascular branches,
Paracrine signaling and
model in the
increased number of
differentiation into
coronary artery
branching points, and
vascular lineage
Delivery of cells
reduced fibrosis,
transfected with
improving cardiac
miRNA (ex vivo)
functions
Rat BMMSCs
Rat MI model
Enhanced tube formation,
increased vessel density
Paracrine signaling
Delivery of cells
transfected with
and reduced fibrosis,
miRNA (ex vivo)
improving myocardial
function
Rat BMMSCs
In vitro only
Increased expressions of
Differentiation into
VEGF a VEGF-A,
vascular lineage
PDGF-B, and TGF-B1
in hypoxic-ischemic
conditions

Cell type
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62

59

58

81

56

40

57

References
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None

Anti-miRNA-222

HUVECs

Cell type

Atelocollagen (local)

None

None

BMMSCs
Paracrine signaling

Thiol-modified analog
Human BMMSCs
of heparin with thiol- Unclear if paracrine
modified hyaluronan
signaling or
and poly(ethylene
differentiation into
glycol) diacrylate
vascular lineage
HP-HA-PEG
(GlycosilTM) (local)
Primary osteoblasts,
Intravenous injection
MC3T3–E1, and
through the tail vein
ATDC5 cells
(systemic) or injection
at the fracture
site (local)

Intradermal injection
(local)

Biomaterial
vehicle/injection

Rat femoral refractory
fracture model
Delivery of antimiRNA

In vitro only

Mouse femoral bone
fracture model
Delivery of antimiRNA

Mouse calvarial bone
defect
Delivery of cells
transfected with
miRNA

Mouse diabetic db/db
model of dermal
wound healing
Delivery of miRNA
(in vivo)

In vivo model

Increased density of blood
vessels and regulated
endogenous
angiogenesis–
osteogenesis coupling,
improving bone
regeneration
Increased blood vessel
volume, number of
CD31+ blood vessels,
and CD31+ capillary
invasion in cartilage,
and higher ratio of
vessel area, increasing
fracture healing
miRNA (not the antimiRNA) decreased
endothelial vessel
growth in a chicken
embryo CAM
angiogenesis assay and
osteogenic
differentiation
Increased capillary
density, accelerating
bone healing through
enhanced osteogenesis,
chondrogenesis, and
angiogenesis

Increased granulation
tissue thickness and
angiogenesis, improving
diabetic wound healing

Outcome

70

71

41

12

24

References

VAPG, Val–Ala–Pro–Gly; TMC-g-PEG-VAPG, trimethyl chitosan-g-poly(ethylene glycol) cRGD; cyclic RGD; PELCL, poly(ethylene glycol)-b-poly(l-lactide-co-e-caprolactone); BMMSC, bone
marrow-derived mesenchymal stem cell; HUVEC, human umbilical vein endothelial cell; RBMEC, rat brain microvascular endothelial cell; SMC, smooth muscle cell; iPSC, induced pluripotent stem
cell; I/R, ischemia/reperfusion; PDGF-B, platelet-derived growth factor-b; TGF-B1, transforming growth factor-b1; CAM, chorioallantoic membrane; MI, myocardial infarction; a-SMA, alphasmooth muscle actin; PLGA, poly(lactic-co-glycolic acid); IBZ, ischemic boundary zone.

Lipofectamine 2000

Lipofectamine 2000

siPORT NeoFX

Lipofectamine 2000

Transfection agent

Anti-miRNA-195

Anti-miRNA-92a

Bone tissue engineering
miRNA-26a

Anti-miRNA-135a-3p

miRNA

Table 3. (Continued)
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the proliferation, migration, and tube formation of ECs,
ameliorating ischemia in the mouse hind limb for PAD
therapy.53 Bonauer et al. also utilized the mouse hind limb
ischemia model to test anti-miRNA-92a by ligation of the
superficial and deep femoral artery and vein.40 They determined that the inhibition of miRNA-92a enhanced the
growth of blood vessels, resulting in significant reduction in
toe necrosis.
Below we discussed other specific applications where the
overexpression or inhibition of miRNA to generate and
engineer blood vessels has been employed.
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Cardiovascular diseases

New blood vessel formation and regeneration are critical
for the treatment of cardiovascular diseases.24 Coronary
artery disease is the most common cause of mortality
worldwide, creating the need for artificial vascular grafts to
aid in cardiovascular diseases.55 However, these grafts remain a challenge because they can lead to thrombosis and
restenosis after implantation,46,47 and thus, other approaches
to treat cardiac diseases are needed. In this study, we discuss
the studies that have investigated the utilization of miRNA
overexpression or inhibition in cardiac dysfunction.
MI, which is also known as a heart attack, is the most
frequent cause of heart failure. Huang et al. used a mouse
acute MI model to investigate the delivery of MSCs
transfected with miRNA-126.56 The MI model was induced by ligating the anterior descending artery of the
animal. Huang et al.56 demonstrated that myocardial
function improved as the delivery of MSCs transfected
with miRNA-126 increased the number of mature microvessels, and increased myocardial blood flow and microvessel density. Bonauer et al. also investigated the
utilization of the inhibition of miRNA-92a for the treatment of MI.40 They showed that the downregulation of
miRNA-92a can lead to improved left ventricular systolic
and diastolic function and reduced infarct size.
Bernardo et al. investigated the inhibition of miRNA-34
family members, which has been seen to be upregulated in
the heart due to stress.57 They saw that inhibition of
miRNA-34 family members (i.e., miRNA-34a, miRNA-34b,
and miRNA-34c) in mice subjected to MI or pressure
overload through transverse aortic constriction resulted in
attenuated pathological remodeling and improved cardiac
function, respectively. Wen et al. used a mouse MI model to
test the delivery of bone marrow-derived mesenchymal stem
cells (BMMSCs) transfected with anti-miR-377 in cardiac
repair.58 They observed enhanced tube formation activity,
increased vessel density, and reduced fibrosis, which led to
improved myocardial function. Xing et al. investigated the
utilization of miRNA-378 for cardiac repair.59 They observed in vitro that overexpression of miRNA-378 in rat
BMMSCs resulted in a larger number of vascular branches
and increased expressions of VEGF-a (VEGF-A), plateletderived growth factor-b (PDGF-B), and transforming
growth factor (TGF)-b1 in hypoxic-ischemic condition.
Skin tissue engineering

Skin engraftment can fail because of the delay or absence in
vascularization.60 Patients who are predisposed to the development of nonhealing skin ulcers face even more challenges
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in vascularizing skin substitutes, which will result in graft
failure.61 Tissue engineering strategies that utilize in vitro
reconstructed skin may be a promising method to replace skin
engraftment and may be utilized for the treatment of wounds
in burn victims or nonhealing wounds in patients with vascular insufficiency, such as those with venous stasis or diabetes or in the elderly patients.61 In addition, the use of
proangiogenic miRNA delivery, as opposed to the traditional
method to induce vascular tissue engineering (i.e., proangiogenic growth factor delivery, which is associated with short
half-lives and instability in vivo), may be a promising skin
tissue engineering approach.
Icli et al. investigated the inhibition of miRNA-135-3p
through injection into mouse dermal wounds (i.e., 1 cm2
dorsal full-thickness skin wounds), which can occur in patients with diabetes mellitus.24 They saw that miRNA-135 was
a pivotal regulator of pathophysiological angiogenesis and
tissue repair, and that inhibition of miRNA-135 induced diabetic wound healing and increased angiogenesis. GallantBehm et al. delivered a synthetic anti-miRNA-92 (i.e., MRG110) to a diabetic mouse skin wound and a normal pig skin
wound model.62 The inhibition of miRNA-92 resulted in the
enhancement of angiogenesis and accelerated wound closure.
Gallant-Behm et al.62 demonstrated that MRG-110 had an
addictive effect with recombinant human platelet-derived
growth factor beta, which is the active ingredient for Becaplermin gel, an Food and Drug Administration-approved
treatment for diabetic foot ulcers (Regranex). MRG-110 is
currently being tested in two phase 1 clinical trials: a systemic
and local administration trial (Clinicaltrials.gov reference
numbers NCT03494712 and NCT03603431, respectively).62
Bone tissue engineering

Compromised vascularity is a limiting factor in successful
bone defect healing, regardless of the approach for bone
tissue engineering.63–65 Insufficient blood supply in the
early phase of bone healing using a tissue engineering system results in inadequate cell integration and cell death in
the system.66 The shortcomings associated with bone tissue
engineering systems, including only addressing osteogenesis, have hindered the use of bone tissue engineering
constructs to replace current therapies. Thus, it is important
to design a bone tissue engineering system that will address
both osteogenesis and angiogenesis.
Several groups have shown the beneficial and synergistic
effects of coupling angiogenesis with osteogenesis for optimal
bone regeneration. VEGF, which is associated with angiogenesis, has been found to directly enhance the mRNA and
protein expression of bone morphogenetic protein 2 (BMP-2),
an osteogenic growth factor that induces osteogenic stem cell
differentiation into osteoblasts.67 Sipola et al.68 and Peng
et al.69 have shown that VEGF and BMP-2 work synergistically in enhancing bone healing by demonstrating that VEGF
antagonists (i.e., endostatin and soluble fms-like tyrosine kinase 1 [sFlt1], respectively) inhibit BMP-2-induced bone
formation. Peng et al.69 further showed that BMP-2-induced
bone formation can be enhanced with exogenous VEGF delivery, which increased angiogenesis and also leads to acceleration in bone formation.
Instead of growth factor delivery for inducing angiogenesis, several groups have also explored the utilization of
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proangiogenic miRNA to promote angiogenesis for bone
tissue engineering. Murata et al. investigated the inhibition
of miRNA-92a in a mouse hip and femoral fracture model.41
They demonstrated that systemic and local administration of
anti-miRNA-92a enhanced bone fracture healing through
increased neovascularization. Li et al. investigated the local
delivery of miR-26a using a biomaterial scaffold in a mouse
calvarial bone defect.12 They saw that miRNA-26a induces
bone regeneration by regulating angiogenesis-osteogenesis
coupling. Yoshizuka et al. investigated the inhibition of
miRNA-222 in a rat femoral refractory fracture model.70
They showed that besides being a negative modulator of
angiogenesis, the inhibition of miRNA-222 could also enhance both osteogenesis and chondrogenesis, potentially
making it a good candidate for endochondral ossification.
Almeida et al. investigated the inhibition of miRNA-196
in vitro.71 They observed that the downregulation of
miRNA-196 resulted in MSC osteogenic differentiation,
proliferation, and control of angiogenesis, and thus may be a
promising tool for human bone defects.
Delivery Vehicle
Biomaterial scaffolds

In tissue regeneration applications, biomaterial scaffolds
can play a vital role in providing a substrate for cells to
adhere and colonize, while also functioning as a delivery
vehicle for the cells and/or bioactive factor of interest, such
as miRNAs or anti-miRNAs. These scaffolds can be made
out of natural polymers, synthetic polymers, bioceramics, or
hydrogels, depending on the targeting tissue of interest and
the delivery cargo (example cells vs. only bioactive factors).
The utilization of biomaterial scaffold delivery of cells
transfected with miRNA or anti-miRNA can be superior to
systemic delivery, as local biomaterial scaffold delivery will
require smaller amounts of costly RNA oligonucleotides and
adverse side effect on nontargeted sites can be avoided.72
The incorporation of the miRNAs into a delivery system
may result in the miRNA being exposed to a harsh environment during the fabrication process such as organic
solvents or heat, and thus, researchers need to make sure that
the miRNAs are stable after incorporation and are nonaffected by the fabrication process. The efficacy of these
miRNAs is evaluated after incorporation into the biomaterials, and thus their stability and bioactivity are confirmed in
the reviewed articles.
Devalliere et al. utilized a collagen-fibronectin-based
scaffold to deliver miRNA-132 to mouse abdominal wall
subcutaneous pockets.45 They showed that the scaffolds
were able to support EC engraftment, and when implanted,
the vascularization site could be better controlled and the
local delivery of miRNA resulted in biological effects in the
area of interest. Natural polymers may be more conducive to
EC engraftment and viability compared to synthetic polymer
scaffolds.
Wen et al. used poly(ethylene glycol)-b-poly(l-lactideco-e-caprolactone) electrospun membranes to deliver
miRNA-145.73 The miRNAs, complexed with a nonviral
vector, were incorporated into the scaffolds by mixing the
complexes into a polymer solution before being electrosprayed. Electrospun materials are ideal for regeneration of
small-diameter blood vessels, as they have high surface area
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and porosity that better mimic the extracellular matrix.73
The membranes investigated by Wen et al.73 were able to
release the complexes for over 56 days.
Yoshizuka et al. utilized atelocollagen to deliver MSCs
transfected with anti-miRNA-222.70 Atelocollagen is a type
of collagen that is made by the elimination of telopeptide
moieties (the antigenic sites of collagen), which decreases
its immunogenicity, making it a safe biomaterial.74 This
material is a liquid at lower temperatures, but solidifies
above 30C, and thus can be used in an injectable delivery
system to slowly release the drug of interest.75
Li et al. used a thiol-modified analog of heparin with
thiol-modified hyaluronan and poly(ethylene glycol) diacrylate (GlycosilTM) biodegradable12 hydrogel to deliver
MSCs transduced with miRNA-26a. Glycosil is available
on the market from ESI$BIO and suitable for 3D cell
culturing.76
Injection

The majority of the reviewed applications were delivered
through local injection at the site of interest instead of utilizing a scaffold. Direct injection of miRNA at the site of
interest is beneficial because of its ease of administration
and it is less invasive, compared to the implantation of a
drug delivery device, which may require a surgery for
placement of the material. Several groups delivered cells
that were transfected with the miRNA or anti-miRNA
in vitro, which were injected in vivo at the site of interest or
systemically. Huang et al. injected miRNA-126 at 5 sites in
peri-infarcted areas in a mouse acute MI model.56 Shu et al.
injected miRNA-93 intramuscularly into the gastrocnemius
muscle in a mouse hind limb ischemia model.53 Qu et al.
injected lentivirus vector containing miRNA-126 stereotactically at 2 mm lateral to the bregma and 2.5 mm deep
under the dura of a focal cerebral ischemia mouse model.51
In the skin tissue engineering of a mouse diabetic wound
healing model, Icli et al. delivered anti-miR-135a-3p intradermally.24
Besides delivering miRNA or anti-miRNA or cells
transfected with miRNA or anti-miRNA through local injection, there were also groups that employed systemic delivery through intravenous injection of the miRNA or antimiRNA. This method may be more easily administered;
however, it may not be as efficient and may result in nontargeted side effects. Murata et al. investigated the systemic
delivery of anti-miRNA-92a intravenously by tail vein injection and compared it to the local injection of antimiRNA-92a at the fracture site in a mouse femoral bone
fracture model.41 They determined that both the local and
systemic delivery enhanced bone healing. Bonauer et al.
systemically delivered anti-miRNA-92a to mouse hind limb
ischemia and acute MI models by intravenous injection.40
Bernardo et al. delivered anti-miRNA-34 systemically by
subcutaneous injection.57
Gene delivery vehicle

Although small in size, the delivery of miRNA into cells
in vitro or in vivo is neither very successful nor efficient
without the aid of a gene delivery vector. miRNAs are
negatively charged biomolecules due to their phosphate
backbone. Thus, miRNA displays coulomb repulsion with
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the cell membrane, which is also negatively charged due to
the lycoproteins and proteoglycans on its surface.77 Therefore, positively charged nonviral vectors or efficient viral
vectors are needed to transfect or transduce, respectively,
miRNA into cells.
Viral. The advantage of viral vectors is its efficient delivery; however, they are also associated with immunogenicity and limitations in insert size.78 Viral vectors that are
often used for gene delivery include lentivirus, retrovirus,
adenovirus, adeno-associated virus, and baculovirus. For the
miRNAs reviewed in this article, only lentivirus was utilized. Lentivirus is a subclass of retroviruses that can
transduce both dividing and nondividing cells.79 Using
lentiviruses, gene expression can be prolonged because the
gene is stably integrated into the host DNA. Huang et al.56
and Qu et al.51 utilized a lentivirus containing plasmid DNA
for miRNA-126. Wen et al. used lentivirus as their gene
delivery vector for anti-miRNA-377.58
Nonviral. Majority of the gene delivery vectors utilized
with the miRNAs discussed in this review were nonviral
vectors, which are easy to obtain and used following the
manufacturers’ protocols and without the need to insert the
miRNA of interest into a virus.
The nonviral gene delivery vector that is most commonly
utilized to transfect nucleic acids, including miRNAs, into
cells is Lipofectamine, a nonviral lipid-based reagent supplied by Invitrogen. It is composed of synthetic cationic
lipids mixed with cholesterol and other lipids.80 The negatively charged miRNAs can form polyplexes with Lipofectamine through electrostatic interactions. The complexes
can be transported into cells by endocytosis and the Lipofectamine can protect the miRNA from enzymatic degradation. In the delivery of angiogenesis-inducing miRNAs,
both Lipofectamine 2000 (suitable for DNA and siRNA)
and Lipofectamine RNAimax (designed specifically for
siRNA and miRNA) have been used by many groups. A few
groups also utilized other manufactured lipid-based nonviral
vectors. Li et al. utilized siPORT NeoFx by Invitrogen,
which was designed for the delivery of siRNAs, to deliver
miRNA-26a.12 Seo et al. utilized siLentFectTM by Biorad,
which was also designed for the delivery of siRNA, to deliver miRNA-146a.81 Gallant-Behm et al. used Dharmafect
reagent by Horizon, which is a siRNA/miRNA lipid-based
vector, to deliver synthetic miR-92a inhibitor (MRG-110),62
and Bonauer et al. used GeneTrans II transfection agent by
MoBiTec GmbH to delivery anti-miRNA-92a.40
Wen et al. utilized Val–Ala–Pro–Gly (VAPG) peptidemodified trimethyl chitosan-g-poly(ethylene glycol) (TMCg-PEG-VAPG) as their nonviral vector to deliver miRNA145.73 Chitosan is a cationic charged natural polysaccharide
polymer, making it ideal to be used to complex with the
negatively charged phosphate backbone of nucleic acids
such as miRNA. The chitosan used in the study, TMC, is
modified by methylation to improve its water solubility and
cationic charge.82,83 Wen et al.73 saw that TMC-g-PEGVAPG with relatively higher molecular weight of chitosan
(50 kDa vs. 5 and 20 kDa) could significantly enhance cellular uptake in SMCs.
Devalliere et al. utilized poly(lactic-co-glycolic acid)
(PLGA) polymer nanoparticles (NPs) to deliver their miR-

1293

NA of interest.45 The NPs were loaded with miR-132 and
coated with cyclic RGD (cRGD) peptides. Before incorporating the miRNA into the NPs during the fabrication process, the miRNA was complexed with spermidine, a
positively charged polyamine that can interact with the
negatively charged miRNA. The NPs were able to prolong
the release of the miRNA for several weeks. Compared to
only using a polymer or lipid-based vector, such as Lipofectamine, the NPs served as depots, as they are in intracellular vesicular compartments, to slowly release the
miRNA into the cytosol. Thus, the particles are able to
better protect the miRNA from degradation. Devalliere
et al.45 demonstrated that the targeted PLGA NPs were good
vehicles to enhance EC transplantation and vascularization
because they were a safe and efficient vehicle.
Targeting agents

Systemic delivery of bioactive factors can result in accumulation of drugs in the mononuclear phagocytic system
cells in the liver, spleen, and bone marrow,84 and also increase hematologic toxicities as a result of circulation
time.85 By using targeting agents for cells at the site of
interest, biomaterials can be used more effectively and efficiently to deliver bioactive factors such as miRNA and
decrease side effects to nontargeted cells.
Wen et al. utilized VAPG, a short peptide that mimics an
elastin-derived peptide sequence to deliver miRNA-145.73 This
peptide sequence can increase the adhesion to vascular SMCs.
Gobin and West suggested that this peptide binds to the b3
integrin subunits of the elastin receptor on SMCs.86 They also
showed that fibroblasts, ECs, and platelets do not adhere to
VAPG, making this targeting agent specific for SMCs.
Devalliere et al.45 coated PLGA NPs with cRGD peptides
that target integrin avb3 expressed on human umbilical vein
ECs (HUVECs).45 This receptor is scarcely detectable in
ECs lining quiescent vessels, but is highly expressed in
proliferating endothelium. Devalliere et al.45 demonstrated a
2.9-fold increase in uptake of the miRNA-loaded NPs in
ECs with RGD peptides.
Cells
Endothelial cells

New vessels are usually formed by transplantation of either mature ECs or committed endothelial progenitor cells.45
To make sure this process is successful and can enhance the
transplantation of ECs, proangiogenic miRNA can be used
to accelerate the rate of vessel formation and maturation.45
The formation of blood vessels can be initiated ex vivo
within a scaffold, which can then be implanted at the targeted site. This is followed by vessel maturation and inosculation in situ. In a hypoxic environment, angiogenesis
occurs and ECs are the primary cells that interface with
blood to sense the change in levels of oxygen and respond to
a depleted oxygen level environment.87 Because of the
primary role of ECs in angiogenesis, many studies utilize
ECs for in vitro experiments and implantation after transfection or transduction of the miRNA of interest. Li et al.
utilized a different source of primary ECs, rat brain microvascular endothelial cells (RBMECs), to investigate the inhibition of miRNA-493.52 Shu et al. utilized EA.hy926 ECs
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with miRNA-93,53 which are a human umbilical vein cell
line.88 EA-hy926 was created by fusing HUVECs with
A549 cells, which are adenocarcinomic human alveolar
basal epithelial cells.88 Compared to HUVECs, which are
primary cells, this cell line grows rapidly in culture and does
not require supplementation of special growth factors, which
can be costly.

Downloaded by 68.201.179.176 from www.liebertpub.com at 01/29/21. For personal use only.

Smooth muscle cells

Besides ECs, vascular smooth muscle (SMC) cells also
play a vital role in the normal stability and formation of
blood vessels. For successful new blood vessel formation,
the contractile and spindle-shaped phenotype need to be
maintained.89–91 However, in pathological or injury conditions, SMCs may be compromised and lead to hyperplasia
and restenosis.92 Wen et al. investigated the transfection of
miRNA-145 released from an electrospun scaffold, into
SMC.73 They showed that miRNA-145 modulated the SMC
phenotype during vascular regeneration. Besides SMCs and
ECs, pericytes are also important cells in blood vessels.
They are fibroblast-like cells that are found wrapped around
22–99% of EC surfaces in arterioles, capillaries, and venules. Thus far, to the best of our knowledge, there are no
applications of angiogenesis-inducing miRNA or antimiRNA with pericytes as their target cells.93
Mesenchymal stem cells

Although human ECs are widely used to improve the
vascularization of skin substitutes, unlike keratinocytes or
fibroblasts, they can produce an immune response.94,95
Autologous ECs can avoid immunological rejection, but
this can be difficult, especially for patients who are prone
to nonhealing wounds.61 Thus, other cell sources are needed for new blood vessel formation for vascular tissue
engineering.
MSCs are employed in many tissue engineering applications because they are known to differentiate into multiple
lineages, including osteoblasts, chondrocytes, adipocytes,
tenocytes, and myocytes.96 MSCs are promising cells for
these applications because they can be easily isolated and
expanded in vitro and have immunologic privilege properties,
making them suitable for xenogeneic implantation. Therefore, these characteristics make MSCs an ideal candidate for
cell therapy in vessel formation for cardiac and vascular
diseases, as well as skin and bone tissue engineering.
However, the differentiation capability of MSCs into the
endothelial lineage for vascularization still remains unclear,97
and there are conflicting findings in the role of MSCs in angiogenesis. MSCs have been shown to be located in the
perivascular region of blood vessels, indicating their contribution to new blood vessel formation, but it is unclear if they
serve as the progenitor cells that differentiate into ECs to form
the blood vessels.97 Several groups have shown that VEGF
stimulation can result in the differentiation of MSCs into ECs.
Oswald et al. showed that treatment of MSCs over the course
of a week upregulated EC surface markers and formed CLS in
Matrigel.98 Similarly, Jazayeri et al.99 and Liu et al.100 observed similar results with MSCs exposed to VEGF with other
growth factors like IGF and FGF.
In contrast, there are also groups such as Roobrouck
et al.101 and Fan et al.102 that have indicated VEGF treatment
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did not result in expression of EC surface markers and did not
form CLS in Matrigel. Furthermore, Au et al. showed that
MSCs were not able to differentiate into ECs and could not
form conduit for blood flow by themselves, and instead, acted
as perivascular precursor cells to support and provide stability
to ECs.103 Thus, there are arguments indicating that MSCs do
not differentiate into ECs or serve as vascular progenitor cells,
but may function to secrete proangiogenic factor to recruit and
induce ECs to form blood vessels instead.
Many studies focus on understanding the role of growth
factors in inducing MSCs into the angiogenic lineage for
vascularization. In this work, we are interested in understanding the role of MSCs in blood vessel formation with
the application of miRNAs that have the ability to induce
angiogenesis as the bioactive factor for the differentiation of
these cells.
MSCs have been delivered for cardiac repair by many
groups, but some studies have shown that there is not much
incorporation of these cells into vascular capillaries, suggesting that MSCs play a different role in helping the repair
process.104 In cardiac injury, MSCs have been utilized by
implantation of the MSCs for the secretion of soluble factors, such as growth factors and cytokines, which can induce
angiogenesis in a paracrine manner.105–108 Several groups
have utilized MSCs in combination with proangiogenic
miRNA for cardiac repair. Huang et al. demonstrated that
the overexpression of miRNA-126 in mouse BMMSCs in a
mouse acute MI model promoted angiogenesis by secreting
VEGF and bFGF for paracrine signaling.56 This resulted in
the increase of microvessel formation at the ischemic tissue.
Li et al. determined that the delivery of miRNA-26a to a
mouse bone calvarial defect model increased EC distribution and density of blood vessels, but it was unclear if the
overexpression of miRNA-26a in the BMMSCs resulted in
the induction of ECs or differentiation of MSCs into ECs.12
Kinnaird et al. demonstrated that MSCs play the role of
secreting cytokines such VEGF and bFGF rather than being
the cells that are incorporated into new or remodeling blood
vessels.106 The injected, labeled MSCs were not incorporated into the blood vessels, suggesting their role confined to
paracrine signaling. Kinnaird et al. showed that the MSC
secretion of cytokines enhanced proliferation and migration
of ECs.104 Almeida et al. demonstrated that miRNA-195
decreased both osteogenesis and the paracrine effect on
angiogenesis by downregulating VEGF mRNA and protein
expression, and thus, the inhibition of miRNA-195 may be a
promising tool for human bone defects.71 Wen et al. showed
that inhibition of miRNA-377 resulted in tube formation of
human umbilical vein ECs and paracrine MSC-induced
angiogenesis58
In addition to contributing to paracrine signaling in cardiac repair, MSCs have also been shown to transdifferentiate
into cardiomyocytes as well as vascular cells.109,110 Seo
et al. demonstrated that overexpression of miRNA-146a increased the secretion of VEGF for paracrine signaling in
angiogenesis, evidenced by the increased formation of vascular branches in human BMMSCs in ischemic/reperfusion
injury.81 Xing et al. showed that BMMSCs transfected with
miRNA-378 had the capacity to form blood vessels and differentiate into the vascular lineage, observed by the larger
number of vascular branches.59 MSCs have demonstrated to
be associated with low survival and apoptosis in hypoxic
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environment.111 However, miRNA-378 has been seen to
enhance MSC proliferation and decrease apoptosis.59
Di Bernardini et al. investigated the overexpression of
miRNA-21 in iPSC differentiation into ECs by the paracrine
secretion of TGF-b2 to neighboring cells.27 Embryonic stem
cells are a promising pluripotent cell source that can differentiate into ECs.112 However, they have conflicting ethical
and immunological issues that make them difficult to employ,27 and thus, iPSCs, somatic cells that are reprogrammed
to an embryonic-like, pluripotent state, may be a more viable
replacement cell source for tissue engineering applications.
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Delivering cells

For most applications reviewed in this article, the miRNA
or anti-miRNA was delivered in vivo in the animal model
chosen. However, there were some groups that delivered
cells transfected with the miRNA or anti-miRNA through a
scaffold or local injection. Di Bernardini et al. delivered
iPSCs transfected with miRNA-21 in a mouse subcutaneous
model.27 Devalliere et al. delivered HUVECs transfected
with miR-132 embedded in a collagen fibronectin gel to a
mouse abdominal wall subcutaneous pocket.45 Li et al. delivered human BMMSCs transfected with miRNA-26a by
the implantation in a thiol-modified analog of heparin with
thiol-modified hyaluronan and poly(ethylene glycol) diacrylate HP-HA-PEG (Glycosil) hydrogel in a mouse calvarial bone defect.12 BMMSCs transfected or transduced
with miRNAs or anti-miRNAs have also been used in vivo
for cardiac disease models.56,58,81 These cells are usually
delivered locally or through intramyocardial injection.
Extracellular Vesicles

Recently, the intercellular transfer of EVs has emerged as
an up-and-coming tool in tissue engineering and, specifically, angiogenesis. EVs, which include exosomes, microvesicles, and apoptotic bodies, are heterogeneous plasma
membrane vesicles that are secreted from most cells under
both normal and stressed conditions.113,114 Unlike living
cells or protein, EVs mediate intercellular communication
through the transport of biological information, including
nucleic acids, lipids, and proteins, to target recipient cells,
triggering downstream signaling events.114,115 EVs hold
advantages to traditional synthetic delivery vehicles due to
their high biocompatibility and limited immunogenicity.116
The effect of EVs on angiogenesis is dependent on the EV
content and surface molecule expression, which can be
modulated by the stimulus that initially induces the EV.117
The functional cargo of EVs that have been shown to
stimulate angiogenesis include miRNAs, lipids, and proteins, including transcription factors.117 EVs, likely composed of both exosomes and microvesicles, are isolated from
the supernatants of cultured cells. The intercellular transport
of angiogenesis-inducing miRNAs has been studied with
EVs collectively or with isolated exosomes and isolated
microvesicles, which are summarized in Table 4.
Exosomes

Exosomes are generally a homogenous population with a
cup-like shape and size ranging from 30 to 120 nm in diameter.118 Exosome formation is derived from the en-
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dosomal system by intraluminal budding of endosomal
compartments that form intraluminal vesicles (ILVs) in intracellular multivesicular bodies, which are mediated by the
endosomal sorting complexes required for transport machinery.119 The ILVs are released as exosomes to the extracellular environment after multivesicular bodies are fused
with the plasma membrane.120
Recent studies have depicted that exosomes derived from
adipose-derived stem cells (ADSC) are key regulators in angiogenesis through the delivery of proangiogenic miRNA.
ADSCs have been found to promote angiogenesis and directly
differentiate into ECs.121 Yang et al. showed that ADSC
exosomes overexpressing miRNA-181b-5p increased migration distance and tube length in RBMECs in vitro.122 In addition, miRNA-199-3p elevated in ADSC exosomes increased
proliferation and migration of endothelial tip cells.123 Liang
et al. demonstrated that miRNA-125a transferred by ADSC
exosomes modulated angiogenesis through promoting tube
formation and endothelial tip cell formation.37
Exosomes derived from BMMSCs have also shown to
promote angiogenesis, mainly when the recipients are ECs.
Liu et al. used BMMSC exosomal-transferred miR-130a in
lithium-incorporated bioglass ceramics to enhance PTEN
and AKT expression, factors that stimulate critical steps in
angiogenesis, in HUVECs.26 Ma et al. also utilized exosomes from BMMSCs for the delivery of miR-132 to recipient HUVECs to stimulate angiogenesis in vivo and
in vitro.124 Exosomal delivered miRNA-132 increased tube
length and mesh number in HUVECs in vitro.124 In an MI
model, mice were subcutaneously injected with HUVECS
pretreated with miR-132 exosomes, which resulted in an
increased number of blood vessels and capillary density in
the infarct area.124
Exosomes are widely present in biological fluids such as
blood, urine, bronchoalveolar lavage fluid, breast milk, synovial fluid, pleural effusions, and ascites.125 Exosomes
derived from the coronary serum of MI patients, carrying
knockdown miRNA-143, have been seen to promote cell
proliferation and tube formation in HUVECs.44
Microvesicles

Microvesicles are generally more heterogenous and larger
in size, ranging from 100 to 1000 nm in diameter, than
exosomes and are formed by the outward blebbing of the
plasma membrane.126,127 Microvesicle formation has been
seen to occur particularly in the lipid-rich microdomains in
the membrane.128,129 Although less extensively studied in
the transfer of miRNAs for angiogenesis, microvesicles
have shown to also promote angiogenesis. In Kang et al., the
delivery of miRNA-31 through microvesicles released from
ADSCs to HUVECs was able to enhance sprouting outgrowth in ex vivo mouse aortic rings and induce vascular
formation in mice in vivo.32
EVs collectively

EVs collectively carrying proangiogenic miRNA have
also been studied for angiogenesis, although not extensively
as isolated exosomes. Wang et al. found that miRNA-210
enriched in BMMSC extracellular vehicles was necessary to
promote angiogenesis in vivo and in vitro.130 Specific
knockdown of miRNA-210 in MSC-EV induced capillary-
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Mouse MI
model

In vitro only

In vitro only

In vitro only

miRNA-132

Anti-miRNA-143

miRNA-181b-5p

miRNA-199-3p

Mouse
peri-infarction
model

In vitro only

EV, production
stimulated
by collagen
biomaterial
EV

Microvesicle

Exosome

Exosome

Exosome

Exosome

Exosome

Exosome

Extracellular
vehicle

Matrigel
injection
(local)

None

Matrigel
implantation
(local)

None

None

None

Intramyocardial
injection

Li-BCG

None

Biomaterial
vehicle/injection

EV derived from
CD34+ cells
Recipient:
HUVECs
EV derived from
mouse BMMSCs
Recipient:
HUVECs

Microvesicle derived from
human ADSCs
Recipient:
HUVECs

Exosome derived from
human ADSCs
Recipient:
human peripheral mononuclear
cells (endothelial tip cells)

Exosome derived from
human-ADSCs
Recipient:
HUVECs
Exosome derived from
rat BMMSCs
Recipient:
HUVECs
Exosome derived from
mouse BMMSCs
Recipient:
HUVECs
Exosome derived from
the coronary serum
of MI patients
Recipient:
HUVECs
Exosome derived from
rat ADSCs
Recipient:
RBMECs

Cell type

Li-BCG, lithium incorporated bioglass ceramics; ADSC, adipose-derived stem cell; EV, extracellular vesicle.

Anti-miRNA-210

EVs collectively
miRNA-21

Mouse
subcutaneous
model

In vitro only

miRNA-130a

Microvesicles
miRNA-31

In vitro only

Application

Exosomes
miRNA-125a

miRNA

Increased capillaries in mouse peri-infarct
regions

Promoted greater capillary-like formation,
increase in HUVEC tubule network
formation

Induced functional vascular formation

Increased migration distance and tube
length in BMECs. Upregulated protein
expression of hypoxia-inducible factor
1a and vascular endothelial cell growth
factor
Increased proliferation and migration in
endothelial tip cells

Promoted cell proliferation and tube
formation

Enhanced expression of proangiogenic
genes (PTEN and AKT) and inhibition
inhibited tube-like structures and
branch nodes
Increased number of blood vessels and
capillary density in infarct area

Promoted tube formation and endothelial
tip cell formation

Outcome

130

131

32

123

122

44

124

26

37

References

Table 4. Proangiogenic microRNAs and Anti-microRNAs Derived from Extracellular Vehicles That Have Been Utilized for Angiogenesis
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like tube formation and newly formed vessels in recipient
HUVECs in vitro. Compared to miRNA-210 silenced in
MSC-EV, control MSC-EV showed more capillaries in
mouse peri-infarct regions in vivo. McNeill et al. used EVs
collectively, which were derived from CD34+ cells to deliver miRNA-21 to HUVECs.131 The production of these
EVs containing miRNA-21 was stimulated by collagen
biomaterial. They demonstrated that this resulted in the
greater capillary-like formation and increase in HUVEC
tubule network formation.
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Gap junction

Besides, through EVs, paracrine signaling has been
studied in co-cultured cells. Fan et al. discovered interestingly, the transfer of miRNA-200b, from osteogenic cells to
vasculogenic cells co-cultured together.132 Rat BMMSCs
are able to form cell-cell interaction with HUVECs through
gap junctions. The loss of miRNA-200b in the BMMSCs
results in the upregulation of VEGF-A, leading to increased
osteogenic differentiation. The increased levels of miRNA200b in HUVECs result in reduced angiogenic potential.
The transfer is triggered by TGF-b that is released from
HUVECs and bound to receptors on BMMSCs.
Conclusion and Future Directions

Proangiogenic miRNAs and anti-miRNAs can be utilized
as therapeutic molecules for vascular tissue engineering in
ischemic diseases, such as in the limbs and the brain (i.e.,
stroke), cardiac disease, as well as skin and bone tissue
engineering. Many studies directly inject miRNAs or antimiRNAs systemically or locally at the site of interest.
However, there are also some studies that apply biomaterials
to control the release of these bioactive factors. Although
ECs, such as HUVECs, are usually the main cells studied
and utilized for these applications, several projects also investigated the use of MSCs. These multipotent cells, when
transfected/transduced with proangiogenic miRNAs or antimiRNAs, can secrete cytokines or growth factors to neighboring cells in paracrine signaling and/or themselves
differentiate into vascular cells.
Most applications utilized the delivery of miRNA or antimiRNA themselves, but some applications relied on the
delivery of cells that have been transfected ex vivo with
miRNA or anti-miRNA, which were then delivered to the
site of interest by implantation in a scaffold or local injection. Aside from the use of viral or nonviral vectors to deliver miRNA, some groups have investigated the delivery of
miRNAs through EVs, including exosomes, microvesicles,
or EVs collectively. As naturally occurring vesicles in the
body, EVs are associated with high biocompatibility and
limited immunogenicity. The production of the miRNAs by
EVs can also be controlled by biomaterials.131
VEGF is the central molecule in the control of angiogenesis, and its expression and subsequent binding to the
VEGFR receptor utilize several signaling pathways, such as
PI3K/AKT, Ras/Raf/MEK/ERK, and p38 MAPK pathways,
to transduce its signal for angiogenesis. Several miRNAs
target VEGF directly and using an inhibitor of the miRNA
(anti-miRNA) can be an angiogenic therapy for vascular
tissue engineering. There are several miRNAs that target
PTEN, a negative regulator of both the PI3K/AKT and Ras/
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Raf/MEK/ERK pathways. Thus, the suppression of PTEN
expression by miRNA will lead to increased signaling of
VEGF through these pathways. Other critical pathways
regulated by miRNAs or anti-miRNAs to enhance angiogenesis include the Notch signaling pathway and the pathway of NO production. HIF-1a and FGF are other molecules
that are also critical in angiogenesis, and their expression
levels can also be controlled by miRNAs or anti-miRNAs.
Although the role of miRNAs and anti-miRNAs to control the production and signal transduction of proangiogenic
factors that therapeutically induce angiogenesis for vascular
tissue engineering is promising, there are limitations and
risks, including the development of hemangioma and reoccurrence of tumors for patients after radiotherapy.133
Many miRNAs investigated for angiogenesis have been
studied for the purposes of antiangiogenic therapies in
cancer, and this implies the risk of negative implications in
cancer of the utilization of proangiogenic miRNA for vascular tissue engineering.
For example, PTEN is a tumor suppressor that is associated with negative outcomes in cancer. However, this
molecule is also targeted by many pro-miRNAs (i.e.,
miRNA-21, miRNA-26a, and miRNA-130a) and inhibition
of this gene may affect its vital role as a tumor suppressor if
not executed correctly. Another example is HIP-1, which is
expressed in tumor cells and is a marker of relapse in
prostate cancer patients in whom the overexpression of HIP1 can lead to tumor formation.134,135 This protein can be
upregulated by anti-miRNA-135a-3p and has been suggested for therapeutic intervention for angiogenesis.24 Thus,
the accuracy and dose of administration are vital to avoid
these side effects and should be a focus for future applications and the utilization of biomaterials can contribute to the
local and targeted delivery of these promising therapeutic
factors.
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